Radiolabeled mGluR2 Ligands for PET Imaging Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved positron emission tomography (PET) radiotracers for imaging the metabotropic glutamate receptor mGluR2, as existing methods lack effectiveness in providing precise and quantitative imaging.
Innovation Solution
Development of specific radiolabeled compounds, such as those described by Formula (I), which are used for imaging mGluR2 receptors in tissues or mammals, utilizing positron-emission tomography, and their corresponding pharmaceutical compositions and methods for preparation and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing radiotracers are used for imaging mGluR2, then imaging can be performed, but the precision and quantification capability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of radiotracer molecules to optimize their binding affinity and selectivity for mGluR2 receptors. Specific structural parameters such as substituent groups, molecular weight, and functional groups are adjusted to improve imaging precision and quantification reliability simultaneously
Solution Approach 2:
The patent develops multiple radiotracer compounds based on a core molecular scaffold, creating variations that replicate and improve upon the binding properties of existing tracers. This allows selection of optimal compounds for precise imaging and quantification
2Loss of information
If existing imaging methods are used, then mGluR2 can be visualized, but quantitative assessment is limited
Solution Approach 1:
The patent implements feedback mechanisms through standardized imaging protocols and quantitative analysis methods that allow iterative optimization of tracer selection and imaging parameters to maximize both information retention and measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable precise and quantitative imaging and quantification of mGluR2 receptors, allowing for the assessment of neurological disorders and potential therapeutic mechanisms, including mood disorders and cognitive dysfunctions.
Implementation Method 1
selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET)
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.